- Home
- NUWE vs GLTO Comparison
NUWE vs GLTO Comparison
Compare NUWE & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- GLTO
- Stock Information
- Founded
- NUWE 1999
- GLTO 2011
- Country
- NUWE United States
- GLTO Denmark
- Employees
- NUWE N/A
- GLTO N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- GLTO Health Care
- Exchange
- NUWE Nasdaq
- GLTO Nasdaq
- Market Cap
- NUWE 3.9M
- GLTO 4.0M
- IPO Year
- NUWE N/A
- GLTO 2020
- Fundamental
- Price
- NUWE $0.40
- GLTO $3.29
- Analyst Decision
- NUWE Strong Buy
- GLTO Buy
- Analyst Count
- NUWE 1
- GLTO 1
- Target Price
- NUWE $17.00
- GLTO $10.00
- AVG Volume (30 Days)
- NUWE 187.8K
- GLTO 86.7K
- Earning Date
- NUWE 05-13-2025
- GLTO 05-08-2025
- Dividend Yield
- NUWE N/A
- GLTO N/A
- EPS Growth
- NUWE N/A
- GLTO N/A
- EPS
- NUWE N/A
- GLTO N/A
- Revenue
- NUWE $8,787,000.00
- GLTO N/A
- Revenue This Year
- NUWE $26.81
- GLTO N/A
- Revenue Next Year
- NUWE $48.74
- GLTO N/A
- P/E Ratio
- NUWE N/A
- GLTO N/A
- Revenue Growth
- NUWE N/A
- GLTO N/A
- 52 Week Low
- NUWE $0.40
- GLTO $2.01
- 52 Week High
- NUWE $8.40
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- NUWE 15.96
- GLTO 59.33
- Support Level
- NUWE $0.76
- GLTO $3.05
- Resistance Level
- NUWE $0.95
- GLTO $3.49
- Average True Range (ATR)
- NUWE 0.09
- GLTO 0.26
- MACD
- NUWE -0.05
- GLTO 0.04
- Stochastic Oscillator
- NUWE 0.00
- GLTO 75.76
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.